Navigation Links
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Date:3/17/2008

Approval Dependent on Outcomes of New Analyses or Confirmatory Trial Conference Call to Discuss Strategy Scheduled for Tuesday March 18, 2008

BERKELEY HEIGHTS, N.J., March 17 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has decided that available data are not adequate to support approval of Genasense(R) (oblimersen sodium) Injection for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). In a decision issued in response to an appeal filed by Genta in October 2007, CDER acknowledged that complete response, which was the primary endpoint in the pivotal trial, was an appropriate endpoint for assessing efficacy. FDA also agreed that this endpoint was achieved, and that those results supported the efficacy of the drug. However, CDER concluded that at present there was insufficient "confirmatory evidence" in the New Drug Application (NDA) to approve the drug.

CDER recommended two alternatives for exploring the efficacy of Genasense that could provide such confirmatory evidence. One option is to conduct an additional clinical trial. The other option is to collect additional information regarding the clinical course and progression of disease in patients from the previous pivotal trial in order to ascertain whether those data contain sufficient confirmatory evidence. The Company currently plans to pursue both of these options.

"In concluding this process, we are pleased that CDER recognized the merit of our completed study, but more importantly has clarified a path to regulatory approval in this important indication," commented Dr. Loretta M. Itri, Genta's President, Pharmac
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
2. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
3. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
11. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 , ... patients, quality of life and treatment satisfaction [ ... ]        ... 2014, 02 September 2014, Barcelona, Spain ... the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation ...
(Date:9/2/2014)... ,S-HERTOGENBOSCH, the Netherlands , Sept. 2, ... expanded its North American operations through its subsidiary HealthLink ... fulfillment and order to cash services for medical device ... our global ERP platform. Building on the ... in Europe with customer service, ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The ... by universal healthcare coverage and good access to ... population and its associated disease burden, well-defined regulatory ... introduction of a new manufacturing policy will drive ... However, a focus on generic substitution and price ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8HealthLink Europe opens North American medical warehouse operation 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
(Date:9/2/2014)... Vancouver, BC (PRWEB) September 02, 2014 ... Research ( http://www.idataresearch.com ), the leading global authority ... urological device market is expected to grow ... be fueled by an increase in the number ... urinary and kidney stones. This market includes TURP ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present its ... Get Up! Get Moving!®. This event promotes Hispanic family physical ... people of all ages and all sizes. The event, which ... at Kiest Park Recreation Center, 3080 S. Hampton Road, in ... 2007, we have partnered with National Alliance for Hispanic Health ...
(Date:9/2/2014)... The American Healthcare Documentation Professionals Group (AHDPG) today ... ICD-10 Medical Coding Bridge Program. The purpose of this ... to students who are seeking to launch an exciting ... the uncertainty brought on by the federal government’s decision ... 2015. , AHDPG’s Free-Tuition Guarantee is simple and available ...
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3
... suffered a set back following the testing by the ... heavy metals in the exported traditional medicinal preparations. // ... by the Health Canada, a part of the Canadian ... highlighted the high concentrations of heavy metals such as ...
... well known. These contain the omega-3 fatty acids EPA and ... has been found that DHA plays an important role in ... women should consume it. ,The alternative to fish-oil supplements ... In this case, the concern is contamination with mercury, which ...
... was associated with several alleged miscarriages of justice has ... ,This decision has been hailed as one to preserve ... health officials in Saskatchewan have voted to curtail practicing ... Charles Smith. ,Smith had been granted ...
... the population is under threat from a drinking problem. This ... Victoria's Centre// for Addictions Research of B.C. compared drinking patterns ... were based on the Canadian Addiction Survey done in 2004. ... exceeded the guidelines for alcohol consumption and 53 per cent ...
... convicted of spreading the dreaded HIV virus since he had ... ,"The message this sends I think is when ... that fact to any perspective partners that you have," commented ... came to testify against Nduwayo were very courageous since they ...
... Disease (GICD) have identified a growth factor in heart development ... diseases. ,the study, published in the online edition ... on the role of short RNAs in the early stages ... called as miRNAs, could play a key role in the ...
Cached Medicine News:Health News:Export Of Ayurvedic Medicines Affected Due To High Heavy Metal Content 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: